He et al. [20] reported that the upregulation of BCL9 was associated with early diagnosis and the degree of malignancy of prostate cancer, revealed by immunohistochemistry, but BCL9 was not an independent biomarker for predicting the non-biochemical recurrence survival rate in prostate cancer patients. Here, BCL9 is linked to prostate carcinoma.